RESCUE
Regimen
- Experimental
- camrelizumab 200 mg Q2W + apatinib 250 mg PO daily
Population
Advanced hepatocellular carcinoma, treatment-naive (1L cohort) or refractory/intolerant to prior 1L targeted therapy (2L cohort). Single-arm phase 2.
Key finding
1L ORR 34.3%, mPFS 5.7 mo, 12-mo OS 74.7%; 2L ORR 22.5%, mPFS 5.5 mo, 12-mo OS 68.2%; 77.4% grade 3+ TRAE (high toxicity); etiology **HBV ~82%** (China-only); provided biology rationale for CARES-310 phase 3
Source: PMID 33087333